Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic p
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic p
复制标题
开始达沙替尼治疗后 1 或 3 个月的分子反应疗效可以预测伊马替尼耐药或伊马替尼不耐受的日本慢性粒细胞白血病患者在慢性期对达沙替尼的反应改善。
作者：
2.Inokuchi K;Kumagai T;Matsuki E;Ohashi K;Shinagawa A;Hatta Y;Takeuchi J;Yoshida C;Wakita H;Kozai Y;Shirasugi Y;Fujisawa S;Iwase O;Yano S;Okamoto S;Oba K;Sakamoto J;Sakamaki H
